雷帕鸣说明书

Instructions for Biocon India:

【Indications】

Rapamune is suitable for patients aged 13 or above who have received kidney transplants to prevent organ rejection. Recommended for use in combination with cyclosporine and corticosteroids.

【Usage and Dosage】

The recommended loading dose of Rapamune for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. Although the loading dose of 15 mg and the maintenance dose of 5 mg/day used in clinical trials are safe and effective, the therapeutic benefits of doses above 2 mg are unclear for kidney transplant patients.

【Adverse reactions】

Common side effects of Rapamune during treatment include lymphocele/peripheral edema/abdominal pain/diarrhea/hypokalemia/increased lactate dehydrogenase/acne/urinary tract infection, etc.

【Notes】

Treatment with Rapamune may result in an increased risk of skin cancer; limit sun and UV exposure; use appropriate sun protection.

Treatment with Rapamune may cause liver damage. Use with caution in patients with hepatic impairment; reduced maintenance dose recommended.

Effective contraceptive measures should be used before starting treatment with rapamin (sirolimus tablets), during treatment and for 12 weeks after stopping treatment. During pregnancy, use Rapamune only if the potential benefits outweigh the potential risks to the embryo/fetus.

Treatment with Rapamune may increase blood lipids (cholesterol and triglycerides). Use with caution in patients with hyperlipidemia. Monitor cholesterol/lipids; if hyperlipidemia occurs, follow current management guidelines (diet, exercise, lipid-lowering agents). Antihyperlipidemic treatments may not be effective in achieving normal levels.

It is already on the market in China, and patients can purchase it at major hospitals or pharmacies in the country with a prescription issued by a doctor. However, the price of its original drug is relatively high, so many patients choose India's Biocon Repamin. Biocon India is one of the three largest biotechnology companies in India and an emerging global biopharmaceutical company dedicated to reducing the cost of treatment for chronic diseases such as diabetes and cancer.

Recommended hot articles: /newsDetail/86887.html